These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Irinotecan for colorectal cancer: a small step forward. O'Connell MJ Lancet; 1998 Oct; 352(9138):1402. PubMed ID: 9807982 [No Abstract] [Full Text] [Related]
23. [Development of cancer chemotherapy. Discovery of new active drugs. IV]. Lopez M Clin Ter; 1999; 150(3):241-9. PubMed ID: 10528439 [No Abstract] [Full Text] [Related]
24. Camptothecins: new enthusiasm for an old drug. Rowe PM Lancet; 1996 Mar; 347(9005):892. PubMed ID: 8622402 [No Abstract] [Full Text] [Related]
25. Are there any better camptothecins than the ones we have? Takimoto CH Clin Adv Hematol Oncol; 2003 Oct; 1(10):578-9, 600. PubMed ID: 16258452 [No Abstract] [Full Text] [Related]
27. DNA topoisomerase I inhibitors. Takimoto CH; Kieffer LV; Arbuck SG Cancer Chemother Biol Response Modif; 1997; 17():80-113. PubMed ID: 9551210 [No Abstract] [Full Text] [Related]
28. Acute presentation of rheumatoid arthritis following cancer chemotherapy using the topoisomerase I inhibitor irinotecan. Yau TC; Chu KW; Mok MY; Liang RH; Epstein RJ Acta Oncol; 2005; 44(7):771-2. PubMed ID: 16227172 [No Abstract] [Full Text] [Related]
29. [Topoisomerase inhibitors developing in Japan]. Furue H Gan To Kagaku Ryoho; 1993 Jan; 20(1):42-9. PubMed ID: 8422186 [TBL] [Abstract][Full Text] [Related]
30. [Current status of camptothecin derivatives as natural antitumor agents]. Pan XD; Wang CY Yao Xue Xue Bao; 2003 Sep; 38(9):715-20. PubMed ID: 14730926 [No Abstract] [Full Text] [Related]
32. The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer. Kim YM; Lee SW; Kim DY; Kim JH; Nam JH; Kim YT J Chemother; 2010 Jun; 22(3):197-200. PubMed ID: 20566426 [TBL] [Abstract][Full Text] [Related]